Tenax Therapeutics (TENX) Debt Ratio (2011 - 2023)

Tenax Therapeutics (TENX) posted quarterly Debt Ratio of 0.05 for Q3 2023, down 71.36% on a QoQ basis from 0.18 in Q4 2022.

Tenax Therapeutics (TENX) Debt Ratio (2011 - 2023) Analysis & Trends

Tenax Therapeutics has reported Debt Ratio for 7 years, with the latest figure at 0.05 in Q3 2023.

Debt Ratio for Q3 2023 came in at 0.05, changed N/A year-over-year; the trailing twelve-month figure through Sep 2023 was 0.05 (changed N/A YoY), and the FY2022 annual result was 0.18, changed N/A from the prior year.
Debt Ratio slipped to 0.05 in Q3 2023, from 0.18 in the prior quarter.
Over five years, Debt Ratio peaked at 0.18 in Q4 2022 and troughed at 0.01 in Q1 2021.
A 4-year average of 0.05 and a median of 0.02 in 2020 frame the typical range for Debt Ratio.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	0.05
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	0.26
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.47
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	0.03
10	Tenax Therapeutics	80.73 Mn	80.73 Mn	-	-

Download Data